Less than half of TikTok videos on RSV prevention offer high-quality info, paper notes
Many people rely on social media to learn more about health conditions and trends. A study published in Vaccine that examined TikTok videos about respiratory syncytial virus (RSV) prevention—including the maternal vaccine (Abrysvo) and the long-acting antibody nirsevimab (Beyfortus) for infants—finds that only 47% present high-quality information.
A study published in Vaccine analyzed TikTok videos discussing respiratory syncytial virus (RSV) prevention, including maternal vaccines Abrysvo and nirsevimab for infants. The research, conducted by authors from Rutgers New Jersey Medical School, found that only 47% of the videos provided high-quality information. The videos, which were posted between July 17, 2023, and November 14, 2025, after the FDA approved nirsevimab, were evaluated using the Global Quality Scale (GQS), with scores ranging from 1 to 5.
A score of 4 or higher was considered high-quality. The median GQS score was 3, with 79 out of 169 videos falling into the high-quality category. Health care professionals created 50.3% of the RSV-prevention videos, followed by parents and caregivers (37.9%), influencers (4.7%), unclear affiliation creators (4.1%), clinics (1.8%), and scientists/researchers (1.2%).
The content of the videos varied, with 20% containing mixed or uncertain information and 3% being misinformation. Despite the overall evidence-consistent nature of the content, nearly one-fifth of the videos were mixed or uncertain. Given the complexity of RSV vaccination recommendations for pregnant people and infants, the authors suggest that clinicians should anticipate families encountering conflicting information online and should direct them to evidence-based resources.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.